CFTR and cystic fibrosis: Since its approval in 2019, the triple CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) has transformed CF care by improving lung function and clinical outcomes in pwCF carrying specific mutations, including the common F508del allele3,4.